Our main objective was to identify the correlation between AR status and CgA level before the administration of anti-AR therapies and in different settings (chemotherapy-naïve and chemotherapy-treated patients) in prostate adenocarcinoma. This evidence concerns the gene CGA and prostate adenocarcinoma.